Browse the evidence

GLP-1 receptor agonists promote significant weight loss in adults with obesity or overweight, with semaglutide 2.4 mg showing superior efficacy compared to placebo and other agents.

For significant weight loss, GLP-1 RAs like semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) are highly effective, producing 15% or more body weight loss in clinical trials. They work by reducing appetite and slowing digestion. While side effects like nausea are common, they often improve over time. These drugs are most effective when combined with lifestyle changes.

Conservative management of obesity requires a structured, multidisciplinary lifestyle intervention (energy-reduced diet, increased physical activity, behavioral therapy) targeting a 5-10% weight loss within 6 months to improve comorbidities.

Start with a modest goal: lose 5-10% of your body weight over 6 months. This is achieved by eating 500-600 calories less per day and moving moderately for 150-300 minutes a week. Work with a team including a doctor and dietitian to make this sustainable.

Pharmacological weight loss therapy is indicated for BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with comorbidities, aiming for ≥ 5% weight loss within 3-4 months of reaching the target dose.

If lifestyle changes alone aren't enough and your BMI is high (≥30 or ≥27 with health issues), ask your doctor about approved weight-loss medications. These are used alongside lifestyle changes and aim for at least 5% weight loss within a few months of reaching the full dose.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (up to 25%) and improve cardiometabolic health, including cardiovascular and renal outcomes.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss and heart health. They work by mimicking hormones that control hunger and metabolism. Discuss these options with your doctor if lifestyle changes alone haven't worked.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (5-15%) and improve cardiometabolic risk factors in adults with obesity, with efficacy increasing with higher doses.

If lifestyle changes alone haven't led to significant weight loss, GLP-1 or dual agonist medications can help you lose 5-15% of your body weight and improve your blood sugar and heart health. These are prescription medications that work by mimicking hormones that control hunger. You will need to start with a low dose and slowly increase it to avoid stomach side effects like nausea.

Phentermine/topiramate combination therapy produces significant weight loss (up to 8.6% vs placebo) and improves metabolic markers, but is contraindicated in patients with unstable cardiovascular disease.

This combination medication can help you lose weight and improve your metabolic health. It works by suppressing appetite and increasing energy expenditure. Because it can affect heart rate and blood pressure, it is not suitable for everyone, especially those with heart conditions. You must start with a low dose and increase it slowly to minimize side effects like tingling or dry mouth.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significantly greater weight loss than older anti-obesity medications (orlistat, phentermine/topiramate, naltrexone/bupropion) by targeting hypothalamic appetite regulation and delaying gastric emptying.

If lifestyle changes alone haven't worked, newer GLP-1 medications (like semaglutide or tirzepatide) are significantly more effective than older drugs, achieving 15-20% weight loss compared to 3-5% with older options. However, they are expensive, require weekly injections (mostly), and can cause gastrointestinal side effects. They are best considered for those with obesity-related comorbidities who have failed lifestyle interventions.

GLP-1 receptor agonists (semaglutide 2.4mg) and dual agonists (tirzepatide 15mg) produce significant, sustained weight loss (11.8% and 14.7-20.9% respectively) compared to placebo, but discontinuation leads to significant weight recurrence (approx. 2/3 of lost weight).

If you qualify (BMI ≥27 with comorbidity or ≥30), GLP-1 agonists like semaglutide (2.4mg weekly) or tirzepatide (15mg weekly) are highly effective, producing 12-21% weight loss. However, these are chronic treatments; stopping them leads to regaining ~2/3 of the weight. Discuss coverage and long-term commitment with your provider.

Type 2 diabetes remission is achievable through significant weight loss (specifically targeting ectopic fat in the liver and pancreas) via very low-calorie diets or bariatric surgery, challenging the view that T2D is an irreversible progressive disease.

To put Type 2 Diabetes into remission, you must lose a significant amount of weight (typically >15kg or >15% of body weight) to remove fat from your liver and pancreas. This is best achieved through a medically supervised Very Low-Calorie Diet (500-800 kcal/day) using meal replacements for 3 months, followed by a structured maintenance plan. This approach is most effective if you have had diabetes for less than 6-10 years.

GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide) and dual/triple agonists induce T2D remission primarily through significant weight loss and reduction of ectopic fat, with some direct beta-cell protective effects.

If you have prediabetes or early Type 2 Diabetes and struggle with weight, GLP-1 or GLP-1/GIP agonists (like Semaglutide or Tirzepatide) are highly effective at restoring normal blood sugar levels. These drugs work by reducing appetite and body weight, with some also having direct benefits on beta-cells. They are often used alongside lifestyle changes.

Semaglutide significantly reduces all-cause mortality and myocardial infarction risk in patients at increased risk of cardiovascular events, with high-certainty evidence.

If you are at high risk for heart issues, semaglutide is a proven treatment that lowers your risk of dying or having a heart attack. While you may experience stomach upset, these side effects are generally not serious and are outweighed by the life-saving benefits. Consult your doctor to see if this medication is appropriate for your specific risk profile.

Intensive lifestyle interventions combining caloric restriction and physical activity significantly reduce body weight and improve metabolic risk factors in overweight and obese adults, although they may not significantly reduce major cardiovascular events compared to standard diabetes support.

To lose weight and improve health markers, you need to combine a moderate calorie deficit (eating 1,200-1,800 kcal/day depending on gender) with regular moderate exercise (at least 150 minutes per week). While this approach significantly improves weight and metabolic health, it may not prevent heart attacks or strokes in high-risk diabetic patients, so medical management remains important. Consistency and behavioral tracking are key to success.

Lifestyle interventions involving diet and exercise are more effective than metformin in preventing the onset of type 2 diabetes in high-risk individuals.

If you are at high risk for diabetes, lifestyle changes are your best defense. Aim to lose 7% of your body weight and get 150 minutes of moderate exercise per week. This approach is significantly more effective at preventing diabetes than taking metformin alone.

Once-weekly subcutaneous semaglutide 2.4 mg, when combined with lifestyle interventions, produces clinically significant weight loss (average 14.9-16.0% body weight reduction) in adults with obesity or overweight with comorbidities, significantly outperforming placebo and daily liraglutide 3.0 mg.

If you have obesity or are overweight with a related health issue, once-weekly semaglutide 2.4 mg is a highly effective tool for weight loss when combined with diet and exercise. It works by mimicking a hormone that slows digestion and reduces appetite. You start with a low dose to minimize stomach upset, then increase it weekly until you reach the full dose. Expect significant weight loss (around 15%) over 6-8 months, which is much more than diet and exercise alone. Be aware of potential side effects like nausea, which usually fade, and avoid the medication if you have a specific family history of thyroid cancer.

Tirzepatide (5-15 mg) produces significantly greater weight loss, waist circumference reduction, and HbA1c improvement compared to placebo, insulin, and GLP-1 receptor agonists in adults with type 2 diabetes or obesity.

Tirzepatide is a highly effective treatment for weight loss and blood sugar control, outperforming existing GLP-1 drugs and insulin. It requires weekly injections and careful dose titration to manage gastrointestinal side effects like nausea.

Combining moderate-to-vigorous aerobic exercise with 3.0 mg/day liraglutide yields superior weight loss maintenance and metabolic health improvements compared to either intervention alone or placebo.

To maintain weight loss effectively, combine daily 3.0 mg liraglutide with a structured exercise routine aiming for 150 minutes of moderate or 75 minutes of vigorous activity per week. This combination is significantly more effective for weight loss and metabolic health than using either method alone.

For patients with Class I obesity (BMI 30–34.9 kg/m2), newer obesity management medications (OMM) such as tirzepatide and semaglutide provide total body weight loss (TBWL) efficacy equivalent to major metabolic bariatric surgeries (MBS) like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB), while offering superior safety and tolerability profiles.

If you have Class I obesity (BMI 30-34.9), you no longer need to choose between surgery and medication as your first step. Newer medications like tirzepatide and semaglutide can help you lose as much weight as major surgeries like gastric bypass, but with fewer risks and side effects. This makes medication a highly effective and safer first-line treatment for this specific group.

Oral vitamin D supplementation at a dose of 700 to 800 IU per day significantly reduces the risk of hip and nonvertebral fractures in elderly persons, whereas a dose of 400 IU per day provides no significant benefit.

If you are over 60, standard 400 IU vitamin D is likely insufficient to prevent fractures. Aim for 700-800 IU daily (cholecalciferol). This dose reduces hip fracture risk by 26% and other fractures by 23%. While many trials included calcium, the high-dose vitamin D effect appears robust even without massive calcium supplementation.

Individualized Medical Nutrition Therapy (MNT) provided by a Registered Dietitian Nutritionist (RDN) significantly improves glycemic control (A1C reduction up to 2.0% in T2D and 1.9% in T1D) and is cost-effective, making it a fundamental component of diabetes management.

Ask your doctor for a referral to a Registered Dietitian Nutritionist (RDN) who specializes in diabetes. Expect about 3-6 visits in the first six months to build your personalized plan, followed by at least one check-in per year. This is covered by Medicare and many insurers. The goal is to lower your A1C and manage weight through sustainable changes tailored to your culture and preferences, not a rigid diet.

Intensive lifestyle interventions modeled on the Diabetes Prevention Program (DPP), including individualized MNT and physical activity, reduce the incidence of type 2 diabetes by 58% in adults with prediabetes and overweight/obesity.

If you have prediabetes and are overweight, ask your doctor about a DPP-modeled lifestyle program. The goal is to lose 7-10% of your body weight and get 150 minutes of moderate exercise per week. This approach is proven to cut your risk of developing type 2 diabetes by more than half. It is often covered by insurance.

Adherence to a Mediterranean dietary pattern significantly reduces the risk of coronary heart disease, an association supported by both strong observational evidence and randomized controlled trials.

Adopt a Mediterranean-style diet by prioritizing vegetables, fruits, nuts, whole grains, and healthy fats (like olive oil) while limiting saturated fats. This pattern is strongly linked to a reduced risk of heart disease in both long-term observational studies and clinical trials.

High intake of trans-fatty acids and foods with a high glycemic index or load significantly increases the risk of coronary heart disease.

Limit intake of trans-fatty acids and foods with a high glycemic index or load, as higher consumption is strongly associated with an increased risk of coronary heart disease.

Moderate intensity endurance training (50% maximal exercise tolerance) is effective for reducing blood pressure, with high-intensity training providing no additional significant benefit.

To lower blood pressure, focus on moderate-intensity endurance exercise (around 50% of your max capacity). You do not need to train at high intensities to get the full blood pressure benefits, which makes this accessible and sustainable for many people.

Caffeine supplementation at low-to-moderate dosages (3-6 mg/kg) significantly enhances sport performance, particularly in endurance and high-intensity team sports, whereas higher dosages (≥9 mg/kg) do not provide further enhancement and may be counterproductive.

If you are a trained athlete, take 3-6 mg of caffeine per kg of body weight about an hour before your event. Do not exceed this range, as higher doses offer no extra benefit and may hurt your performance. Anhydrous caffeine (capsules/powder) is more effective than coffee, but coffee is still better than nothing if you prefer it.